|Articles|March 1, 2011
- BioPharm International-03-02-2011
- Volume 2011 Supplement
- Issue 2
BioPharm International, March 2011 Supplement (PDF)
Global Outsourcing
Advertisement
Articles in this issue
almost 15 years ago
Supply-Chain Transformation: Strategic Necessity for the Life Sciencesalmost 15 years ago
Key Considerations When Outsourcing Cell-Culture Medium Developmentalmost 15 years ago
Sponsor-CMO Conflict Management for Clinical-Phase BiologicsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Neurimmune and AstraZeneca Expand Efforts to Accelerate Fibril-Depleting Therapies
2
New Draft Guidance Highlights FDA Push Toward Human-Relevant Safety Models
3
New Lymphoma Indication for CAR T-Cell Therapy Shapes Pipeline
4
Regulatory Uncertainty Surfaces as FDA Blames COVID Vaccines for 10 Child Deaths
5
